A Study of OV101 in Individuals With Angelman Syndrome (AS)
Phase 3
Completed
- Conditions
- Primary Disease or Condition Being Studied: Angelman Syndrome (AS)
- Interventions
- Drug: PlaceboDrug: Gaboxadol
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Ovid Therapeutics Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT04106557
- Locations
- ๐ณ๐ฑ
Ovid Therapeutics Investigative Site, Rotterdam, Netherlands
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome
Phase 3
Terminated
- Conditions
- Angelman Syndrome
- Interventions
- Drug: OV101
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Ovid Therapeutics Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT03882918
- Locations
- ๐ฎ๐ฑ
Ovid Therapeutics Investigative Site, Ramat Gan, Israel
A Study of OV101 in Individuals With Fragile X Syndrome
Phase 2
Completed
- Conditions
- Fragile X Syndrome (FXS)
- Interventions
- Drug: OV101 (gaboxadol)
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Ovid Therapeutics Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03697161
- Locations
- ๐บ๐ธ
Ovid Therapeutics Investigative Site, Nashville, Tennessee, United States
Single Dose Pharmacokinetic (PK) Study
Phase 1
Completed
- Conditions
- Angelman SyndromeFragile X Syndrome
- Interventions
- Drug: OV101
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- Ovid Therapeutics Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03109756
- Locations
- ๐บ๐ธ
Ovid Therapeutics Investigative Site, Nashville, Tennessee, United States
A Study in Adults and Adolescents With Angelman Syndrome (STARS)
Phase 2
Completed
- Conditions
- Angelman Syndrome
- Interventions
- Drug: OV101 regimen 2Other: PlaceboDrug: OV101 Regimen 1
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Ovid Therapeutics Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT02996305
- Locations
- ๐ฎ๐ฑ
Ovid Therapeutics Investigative Site, Ramat Gan, Israel
ยฉ Copyright 2025. All Rights Reserved by MedPath